DACE

Awesome to see this. Really excited about the 1-person biotech in particular. CROs with APIs available for agents like @ginkgo’s Datapoints service plus something like a “cursor for biotech” could really change the cost of launching biotech startups.

Great to see the leadership from @SecScottBessent adding biotechnology to the COINS Act list of strategic technologies. We've been hollowing out the US biotechnology startup ecosystem with newly acquired drugs originating in Chinese startups going from roughly 0% to 50% over the last 5 years. This puts US control of the frontier of biotechnology at risk in exchange for lower cost scientist labor and looser clinical trial regulations in China. To add insult to injury -- US patients are the source of 70-80% of the *worldwide* profits in pharmaceuticals! The US spends $700B per year on the newest, branded drugs while China only spends $60B per year on the same drugs with 4X the population! If the CCP wants to control the frontier of biotech there is an easy way to do it -- they should pay a fair price for pharmaceuticals to support a domestic ecosystem. But the CCP requiring that Chinese patients pay 1/10th to 1/40th the price for the same drugs compared to US patients (meanwhile iPhones are more expensive in China!) while also trying to offshore a dual use strategic technology is way across the line. Well done by Treasury in waking up to this bad deal for the US and starting the remedy. Huge win today for US biotechnology ("little pharma") and national security 👏👏👏